指南与共识眼底病与葡萄膜炎

高剂量抗VEGF治疗新生血管性年龄相关性黄斑变性中国专家共识(2026)

[Chinese expert consensus on high-dose anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration (2026)].
指南 / 共识 · Zhonghua Yan Ke Za Zhi · 2026-01-01

该共识由中国罕见病联盟/北京罕见病诊疗与保障学会眼科分会组织多学科专家组制定,针对高剂量抗VEGF药物治疗nAMD的8个临床问题提出共识性推荐意见。共识基于最新循证医学证据并结合国际指南与中国临床实践,旨在规范高剂量抗VEGF药物的应用,提高中国nAMD的诊疗和长期管理水平。

要点

  • 抗VEGF玻璃体腔注射是nAMD一线治疗,但存在给药频次高和治疗负担重的问题。
  • 高剂量抗VEGF药物为延长给药间隔和优化长期管理提供了新策略。
  • 共识围绕8个临床问题提出推荐意见,规范高剂量抗VEGF药物的应用。

核心结论

  • 高剂量抗VEGF药物可为nAMD治疗提供延长给药间隔和优化长期管理的新策略。

研究设计与样本

  • 由中国罕见病联盟/北京罕见病诊疗与保障学会眼科分会组织多学科专家组制定共识。
  • 采用规范的共识制订方法,基于最新循证医学证据并结合国际指南与中国临床实践。

主要发现

  • nAMD以异常脉络膜新生血管形成为主要病理特征,可导致明显视力损伤。
  • 抗VEGF药物玻璃体腔注射是nAMD标准一线治疗,但存在给药频次高、治疗负担较重及部分患者疗效不佳等问题。
  • 高剂量抗VEGF药物围绕8个临床问题形成共识性推荐意见。

关键数值与推荐

  • 共识针对高剂量抗VEGF药物治疗nAMD的8个临床问题提出推荐意见。

临床怎么用

  • 为高剂量抗VEGF药物规范治疗nAMD提供循证依据、临床指导和参考。
  • 旨在提高中国nAMD的规范化诊疗和长期管理水平。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Neovascular age-related macular degeneration (nAMD) is primarily characterized by the formation of abnormal choroidal neovascularization and can lead to substantial visual impairment. Intravitreal administration of anti-vascular endothelial growth factor (anti-VEGF) agents has become the standard first-line treatment for nAMD. However, challenges remain, including the need for frequent injections, considerable treatment burden, and suboptimal responses in a subset of patients. In recent years, the emergence of high-dose anti-VEGF therapies has provided a novel strategy for extending treatment intervals and optimizing long-term disease management. To address these clinical needs, the Ophthalmology Group of China Alliance for Rare Diseases/Beijing Society of Rare Disease Clinical Care and Accessibility organized a multidisciplinary panel of experts to develop this consensus. Based on the latest evidence-based medical findings, together with international guidelines and the realities of clinical practice in China, a standardized consensus-development methodology was employed. Consensus recommendations were formulated for eight key clinical questions regarding the use of high-dose anti-VEGF therapies in the treatment of nAMD. The aim of this document is to provide evidence-based guidance and clinical reference for the standardized application of high-dose anti-VEGF therapies in nAMD, thereby further improving the quality of standardized diagnosis, treatment, and long-term management of nAMD in China. 新生血管性年龄相关性黄斑变性(nAMD)以异常脉络膜新生血管形成为主要病理特征,可导致明显视力损伤。玻璃体腔注射抗血管内皮生长因子(VEGF)药物已成为治疗nAMD的一线方法,但存在给药频次高、治疗负担较重及部分患者疗效不佳等问题。近年高剂量抗VEGF药物的应用,为延长给药间隔时间和优化长期治疗管理提供了新的策略。鉴于此,中国罕见病联盟/北京罕见病诊疗与保障学会眼科分会组织相关领域专家,基于最新循证医学证据,并结合国际指南及中国临床实践现状,采用规范的制订方法,围绕高剂量抗VEGF药物治疗nAMD的8个临床问题,提出共识性推荐意见,旨在为高剂量抗VEGF药物规范治疗nAMD提供循证依据、临床指导和参考,进一步提高中国nAMD的规范化诊疗和长期管理水平。.

来源:Zhonghua Yan Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. [Chinese expert consensus on high-dose anti-vascular endothelial growth factor therapy for neovascular age-related macular degeneration (2026)]. Zhonghua Yan Ke Za Zhi. 2026. PMID: 42855777. doi:10.3760/cma.j.cn112142-20260525-00227

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。